Abstracts

1005 – Renal Impairment in People Living With HIV or Receiving PrEP: A Prospective, Matched-Cohort Study

Background HIV preexposure prophylaxis (PrEP) with fixed-dose tenofovir disoproxil fumarate (TDF) and emtricitabine has been associated with relatively low rates of renal impairment in clinical trials, and renal toxicity has been considered less frequent than that observed in people living with HIV (PLWH).  Methods In a matched-cohort study, both TDF-treated PLWH and those receiving TDF-based…

567 – Twice-Yearly Lenacapavir, Teropavimab, and Zinlirvimab for HIV-1: Week 52 Resistance Analyses

Background Lenacapavir (LEN) and broadly neutralizing antibodies, teropavimab (TAB) and zinlirvimab (ZAB), have pharmacokinetic profiles supporting twice-yearly dosing. In a Phase 2 study (NCT05729568), twice-yearly LEN, TAB, and ZAB maintained a high rate (89%) of virological suppression (HIV-1 RNA <50 copies/mL) at Week (W) 52. We describe resistance analyses through W52. Methods Virologically suppressed participants…

1044 – Doxy-PEP Knowledge, Attitudes, and Practices Among HIV and PrEP Providers: A Pilot Study

Background Doxycycline post-exposure prophylaxis (doxy-PEP) effectively prevents bacterial STIs among men who have sex with men (MSM) and transgender women (TGW). The real-world impact of doxy-PEP will depend partly on provider willingness to prescribe, yet data on provider knowledge, attitudes, and practices (KAP) remain limited. Methods We conducted a cross-sectional pilot survey (May–September 2025) among…

865 – Updated Global Mortality Estimates for Children Aged <15 Years on Antiretroviral Therapy From IeDEA

Background Mortality data from the International epidemiology Databases to Evaluate AIDS (IeDEA) consortium inform models used by UNAIDS to estimate the number of children (aged <15 years) living with HIV (CLHIV) and AIDS-related deaths annually. Previous IeDEA mortality estimates used data up to 2017.  We updated all-cause mortality among CLHIV on ART and described trends…

867 – Effects of Dolutegravir on Growth of Children and Adolescents Living With HIV: IeDEA Global Cohort

Background In adults, dolutegravir (DTG)-based antiretroviral therapy (ART) has been linked with excess weight gain. However, pediatric data remain limited and inconsistent. We examined growth trajectories, measured by BMI-for-age z-scores (zBMI), among children and adolescents living with HIV (CALHIV) initiating DTG.  Methods CALHIV aged 1 month–19 years from the International epidemiology Databases to Evaluate AIDS (IeDEA) cohorts…

615 – Point-of-Care HCV RNA Compared to Laboratory-Based HCV RNA in a Tribal Health Setting

Background American Indian/Alaska Native (AI/AN) people experience disproportionately high rates of hepatitis C virus (HCV) infection. In 2024, an FDA-approved point-of-care (PoC) HCV RNA test was integrated into community-based screening efforts within Cherokee Nation to expand access and improve linkage to care for underserved, high-risk individuals. The objective of this study is to assess how PoC versus laboratory-based…

343 – Gut Microbiome Is Linked to Intact HIV-1 Reservoir Size

Background The gut microbiome is altered during HIV infection, driving immune dysfunction and inflammation in people with HIV (PWH) that persists despite antiretroviral therapy (ART). In this study, we explored the associations between the gut microbiome composition, the metabolic pathways and the intact HIV-1 reservoir size in PWH on effective ART. Methods Blood and fecal…

646 – Association of HIV Reservoir With Subclinical Myocardial Dysfunction in People With HIV

Background People with HIV remain at higher cardiovascular risk despite long-term ART. Subclinical myocardial impairment, often missed by conventional echocardiography, can be detected using strain-derived myocardial work indices. We aimed to assess early myocardial dysfunction in PWH and its relationship with the HIV reservoir to better understand the higher cardiovascular risk in this population. Methods…

871 – Depression, Anxiety, and Viral Suppression Among Adolescents and Young Adults in 9 African Countries

Background Adolescents and young adults living with HIV (ALWH) have the lowest viral suppression rates of all age groups. Depression and anxiety may undermine treatment outcomes yet have not been systematically assessed among ALWH in Africa at scale. Using population-representative data, we estimated the prevalence of depressive and anxiety symptoms among ALWH and their association…